January 9, 2019
Protagonists kicks off phase 2 testing PTG-300 with patients with beta thalassemia
Protagonist Therapeutics has injected mimetic peptide (PTG-300) into patients with beta thalassemia, to test it in a study to make it a treatment for this rare disease.